Obesity, endogenous hormone metabolism, and prostate cancer risk: A conundrum of "highs" and "lows"

Cancer Prevention Research

Volumn 3, Issue 3, 2010, Pages 259-262

  Kaaks, Rudolf ^a   Stattin, Pär ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

ANDROGEN METABOLISM; BODY MASS; CANCER GRADING; CANCER RISK; DIABETES MELLITUS; DRUG EFFECT; HISTOPATHOLOGY; HORMONE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SCORING SYSTEM;

ANDROGENS; BODY MASS INDEX; HUMANS; INSULIN; MALE; OBESITY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77949665197     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0014     Document Type: Review

References (30)

1. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
2. Hsing AW, Sakoda LC, Chua S, Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007;86:s843-57.
3. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91-106.
4. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009;115:86-96.
5. Stocks T, Lukanova A, Rinaldi S, et al. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 2007;120:2678-86.
6. Neuhouser ML, Till C, Kristal AR, et al. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Can Prev Res 2010;3:279-89.
7. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
8. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008;9:1039-47.
9. Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009;101:1272-9.
10. Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1366-74.
11. D'Amico AV, Barry MJ. Prostate cancer prevention and finasteride. J Urol 2006;176:2010-2.
12. King CR, Long JP. Prostate biopsy grading errors: a sampling problem? Int J Cancer 2000;90:326-30.
13. Kulkarni GS, Al-Azab R, Lockwood G, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006;175:505-9.
14. Mir MC, Planas J, Raventos CX, et al. Is there a relationship between prostate volume and Gleason score? BJU Int 2008;102:563-5.
15. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006;370:89-93.
16. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562-8.
17. Muller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H. Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev 2009;18:1350-6.
18. Grubb RL III, Black A, Izmirlian G, et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2009;18:748-51.
19. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006;15:1977-83.
20. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009;124:1398-403.
21. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005;161:147-52.
22. Leitzmann MF, Ahn J, Albanes D, et al. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 2008;19:1267-76.
23. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of diabetes with prostate cancer risk in the multi-ethnic cohort. Am J Epidemiol 2009;169:937-45.
24. Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 2000;3:157-72.
25. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83.
26. Hsing AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer: Is the hypothesis dead? Cancer Epidemiol Biomarkers Prev 2008;17:2525-30.
27. Kaplan SA, Roehrborn CG, Meehan AG, et al. PCPT: evidence that finasteride reduces risk of most frequently detected intermediate-and high-grade (Gleason score 6 and 7) cancer. Urology 2009;73:935-9.
28. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83.
29. Roehrborn CG, Lee M, Meehan A, Waldstreicher J. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology 2003;62:894-9.
30. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5.